Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

PHASE2WithdrawnINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
MelanomaMalignant Melanoma
Interventions
DRUG

lovastatin

lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals

DRUG

interferon alfa-2b

interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly

Trial Locations (1)

37027

NeoPlas Innovation, Nashville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

NeoPlas Innovation

OTHER